达普司他有几种规格?多少钱?

Daprostat is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI). Its specifications are designed to cover multi-dimensional needs such as clinical treatment, dose adjustment, and scientific research experiments. The price varies significantly depending on the version, specifications, and purchasing channels. As of May 6, 2025, the drug has not yet been launched in China. Patients need to obtain it through cross-border drug purchase or clinical trials. They need to choose an adaptation plan based on the medication cycle, dosage requirements and economic ability.

Daprostat is available in several strengths

The differentiation of strengths is closely related to its clinical positioning, dosing flexibility and experimental needs. Patients need to choose the appropriate strength based on the treatment stage, dose adjustment needs and compliance requirements.

Clinical treatment specifications

The clinical treatment specifications of daprostat include 1mg, 2mg, 4mg, 6mg and 8mg tablets, and the packaging capacity of a single bottle is usually 100 tablets. Taking the 4mg specification as an example, it uses PTP (blister packaging) technology, and the dosage of a single tablet can be flexibly divided to 1-4mg per day, which is suitable for dose adjustment during the maintenance period.

Specifications of generic drugs

The Laos Lucius version of generic daprostat is 1mg*100 tablets, and the price is relatively affordable.

How much does the different specifications of daprostat cost?

The price system of daprostat is significantly affected by R&D cost allocation, production scale effect and market access policy. Patients need to choose a purchasing plan based on the medication cycle, dose adjustment needs and compliance requirements.

Price of generic drugs

Daprostat, produced by Lucius Pharmaceuticals in Laos, is priced at about US$6 per box for 1 mg × 100 tablets, and the cost of a single day's treatment is less than US$0.1.

The price of the original drug

The price of the original drug Daprostat developed by GlaxoSmithKline (GSK) is temporarily unclear, but the price is usually higher.

Daprostat Precautions

The clinical application of daprostat must strictly follow the scope of indications, dose adjustment principles and contraindication screening. Patients must establish a standardized medication process to avoid treatment interruption or serious adverse reactions due to improper operation.

Hypersensitivity reaction monitoring

Daprostat may cause hypersensitivity reactions such as bronchospasm, chest pain, and dyspnea, with an incidence rate of less than 1%. Patients need to monitor their hemoglobin levels every 2 weeks after taking the medication. If bronchospasm or dyspnea occurs, the medication must be discontinued immediately and intravenous epinephrine should be administered.

Contraindications Screening

Daprostat is contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency because hydrogen peroxide by-products may cause hemolytic anemia. Clinical studies have shown that hemolytic reactions occur 2-4 days after administration, and severe cases require blood transfusion support. If Chinese patients have African or Mediterranean ancestry, they need to screen for G6PD activity before taking the drug. If it is lower than 60% of the normal value, it is disabled. For patients with methemoglobinemia, blood oxygen saturation needs to be monitored. If it is lower than 90%, the drug must be stopped immediately and methylene blue (1-2 mg/kg) must be given intravenously.

Laboratory test interference

Daprostat may interfere with uric acid determination, resulting in falsely low plasma uric acid readings. If you need to detect uric acid levels, you need to use blood collection tubes containing urate oxidase inhibitors, or use high-performance liquid chromatography (HPLC) for quantitative analysis.

Such interference is particularly significant in scientific research experiments. If sample processing procedures are not followed, it may lead to failure in constructing a pharmacodynamic model.